We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Merin, director of the leukemia program at Cedars-Sinai ...

In this video, Douglas Tremblay, MD, discusses the results of a study into a first-line treatment of chronic myelomonocytic leukemia presented at ESMO Congress 2024. Tremblay, an assistant professor ...

– Complete remission (CR) rate of 50% and overall response rate (ORR) of 66.7% in 18 evaluable patients with CMML treated with IO-202 in combination with azacitidine – – CR rate of 83.3% and ORR of ...

Phase 1a of the trial examined dose escalation of IO-202 as a monotherapy and in combination with azacitidine. Phase 1b of the trial studied dose expansion data of IO-202 in combination with ...

BOSTON, Dec. 2, 2024 /PRNewswire/ -- Solu Therapeutics ("Solu Therapeutics" or "Solu"), a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and ...

The regimen of bexmarilimab and azacitidine (Vidaza) demonstrated a highly promising efficacy profile with a manageable ...

The impact of the use of hypomethylating agents prior to reduced intensity conditioning allogeneic bone marrow transplant among patients with MDS. This is an ASCO Meeting Abstract from the 2025 ASCO ...

CR or mCR in 86% of patients within the first 12 months - Venetoclax-resistant secondary AML transformed from CMML responds to lenzilumab BURLINGAME, CA / ACCESS Newswire / November 4, 2025 / Taran ...

BOSTON, Dec. 9, 2024 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today ...